Literature DB >> 16932303

Niacin in the metabolic syndrome: more risk than benefit?

Henry N Ginsberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16932303     DOI： 10.1038/ncpendmet0199

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  4 in total

Review 1.  Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.

Authors:  Insug Kang; Sang-Wook Kim; Jang H Youn
Journal:  J Clin Endocrinol Metab       Date:  2011-08-03       Impact factor: 5.958

Review 2.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

Review 3.  The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.

Authors:  Henry N Ginsberg; Paul R Maccallum
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-09       Impact factor: 3.738

4.  B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study.

Authors:  Shi-Sheng Zhou; Da Li; Yi-Ming Zhou; Wu-Ping Sun; Qi-Gui Liu
Journal:  BMC Public Health       Date:  2010-12-02       Impact factor: 3.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.